Evaluation of the safety of PD-1/PD-L1 inhibitors for immunotherapy in patients with malignant tumors after COVID-19 infection: A single-center cohort study.

Publication date: Oct 01, 2024

An increasing body of evidence suggests a close association between COVID-19 infection and the safety of PD-1/PD-L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. We conducted a retrospective analysis of cancer patients who received PD-1/PD-L1 inhibitor therapy at the same institution from November 2022 to May 2023. After excluding patients with missing information, a total of 224 cases were included. In our study, immune-related adverse events (irAEs) that occurred during the hospitalization of patients were included in the analysis. Further analysis of inter-subgroup differences was conducted following a 1:2 propensity score matching. Statistical analyses were performed using the Fisher’s exact, chi-squared, and Mann-Whitney U-tests. The results showed that no statistically significant differences between the two subgroups in the incidence of irAEs, changes in immune function before and after using PD-1/PD-L1 inhibitors, and alterations in hepatic and renal function (p > 0. 05). Our findings suggest that infection with COVID-19 does not significantly impact the safety of PD-1/PD-L1 inhibitors in cancer patients. Most cancer patients used PD-1/PD-L1 inhibitors during COVID-19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects.

Open Access PDF

Concepts Keywords
Immunotherapy Adult
Malignant Aged
November Aged, 80 and over
Renal B7-H1 Antigen
Retrospective B7-H1 Antigen
cancer
CD274 protein, human
COVID-19
COVID‐19 infection
Female
Humans
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors
Immunotherapy
Male
Middle Aged
Neoplasms
PDCD1 protein, human
propensity score matching
Retrospective Studies
SARS-CoV-2

Semantics

Type Source Name
disease MESH tumors
disease MESH COVID-19
disease MESH infection
drug DRUGBANK Coenzyme M
pathway REACTOME Reproduction
disease MESH metastasis
disease IDO blood
pathway REACTOME Immune System
disease IDO nucleic acid
drug DRUGBANK Methionine
disease IDO history
drug DRUGBANK Trestolone
drug DRUGBANK Nesiritide
drug DRUGBANK Oxygen
disease MESH functional status
disease IDO process
disease MESH liver cancer
disease MESH hypertension
disease MESH cardiac arrhythmia
disease MESH hypoproteinemia
disease MESH hypothyroidism
disease MESH anemia
disease MESH Hepatitis
disease MESH cerebral infarction
disease MESH Nasopharyngeal carcinoma
drug DRUGBANK Durvalumab
drug DRUGBANK Nivolumab
drug DRUGBANK Creatinine
drug DRUGBANK Uric Acid
disease MESH lung cancer
disease MESH Drug induced liver injury
disease MESH enteritis
disease IDO immune response
disease MESH bundle branch block
disease MESH respiratory distress syndrome
disease MESH Coronavirus Infection
disease IDO virulence
disease MESH hematological neoplasms
disease MESH carcinoma
disease MESH microsatellite instability
disease MESH heart disease
drug DRUGBANK Docetaxel
drug DRUGBANK Platinum
disease MESH complications
disease MESH death
drug DRUGBANK Isosorbide Mononitrate
disease IDO cell

Original Article

(Visited 7 times, 1 visits today)